• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

肺癌的新治疗策略

New Therapeutic Strategies for Lung Cancer.

作者信息

Icard Philippe, Damotte Diane, Alifano Marco

机构信息

Thoracic Surgery, Cochin Hospital, AP-HP Centre-University of Paris, 75014 Paris, France.

Inserm U1086 Interdisciplinary Research Unit for Cancer Prevention and Treatment, Normandy University, 14000 Caen, France.

出版信息

Cancers (Basel). 2021 Apr 16;13(8):1937. doi: 10.3390/cancers13081937.

DOI:10.3390/cancers13081937
PMID:33923765
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8072685/
Abstract

Non-small cell lung cancer (NSCLC) accounts for approximately 27% of all cancer-related deaths worldwide, thus representing a major health problem [...].

摘要

非小细胞肺癌（NSCLC）约占全球所有癌症相关死亡人数的27%，因此是一个重大的健康问题[...]。

相似文献

1
New Therapeutic Strategies for Lung Cancer.肺癌的新治疗策略
Cancers (Basel). 2021 Apr 16;13(8):1937. doi: 10.3390/cancers13081937.
2
Th17 cell-derived IL-17A promoted tumor progression via STAT3/NF-κB/Notch1 signaling in non-small cell lung cancer.辅助性T细胞17（Th17）细胞衍生的白细胞介素-17A（IL-17A）通过信号转导和转录激活因子3（STAT3）/核因子κB（NF-κB）/Notch1信号通路促进非小细胞肺癌的肿瘤进展。
Oncoimmunology. 2018 Aug 23;7(11):e1461303. doi: 10.1080/2162402X.2018.1461303. eCollection 2018.
3
Interleukin-35 Expression in Non-Small Cell Lung Cancer is Associated with Tumor Progression.白细胞介素-35在非小细胞肺癌中的表达与肿瘤进展相关。
Cell Physiol Biochem. 2018;51(4):1839-1851. doi: 10.1159/000495706. Epub 2018 Nov 30.
4
miR-196b-5p-mediated downregulation of TSPAN12 and GATA6 promotes tumor progression in non-small cell lung cancer.miR-196b-5p 下调 TSPAN12 和 GATA6 促进非小细胞肺癌的肿瘤进展。
Proc Natl Acad Sci U S A. 2020 Feb 25;117(8):4347-4357. doi: 10.1073/pnas.1917531117. Epub 2020 Feb 10.
5
Upregulation of LncRNA-HIT promotes migration and invasion of non-small cell lung cancer cells by association with ZEB1.长链非编码RNA-HIT的上调通过与锌指E盒结合蛋白1相互作用促进非小细胞肺癌细胞的迁移和侵袭。
Cancer Med. 2016 Dec;5(12):3555-3563. doi: 10.1002/cam4.948. Epub 2016 Oct 27.
6
GRK5 functions as an oncogenic factor in non-small-cell lung cancer.GRK5 在非小细胞肺癌中充当致癌因子。
Cell Death Dis. 2018 Feb 20;9(3):295. doi: 10.1038/s41419-018-0299-1.
7
lncRNA CCHE1 increased proliferation, metastasis and invasion of non-small lung cancer cells and predicted poor survival in non-small lung cancer patients.长链非编码 RNA CCHE1 促进非小细胞肺癌细胞的增殖、转移和侵袭，并预测非小细胞肺癌患者的预后不良。
Eur Rev Med Pharmacol Sci. 2018 Mar;22(6):1686-1692. doi: 10.26355/eurrev_201803_14581.
8
Role of cytokines in combinatorial immunotherapeutics of non-small cell lung cancer through systems perspective.从系统角度看细胞因子在非小细胞肺癌联合免疫治疗中的作用。
Cancer Med. 2019 May;8(5):1976-1995. doi: 10.1002/cam4.2112. Epub 2019 Apr 17.
9
Current status of research and treatment for non-small cell lung cancer in never-smoking females.从不吸烟女性非小细胞肺癌的研究与治疗现状
Cancer Biol Ther. 2017 Jun 3;18(6):359-368. doi: 10.1080/15384047.2017.1323580. Epub 2017 May 11.
10
The role of new agents in the treatment of non-small cell lung cancer.新型药物在非小细胞肺癌治疗中的作用。
Eur J Cancer. 2002 Dec;38(18):2347-61. doi: 10.1016/s0959-8049(02)00457-4.

引用本文的文献

1
Mesenchymal Stem Cell-Conditioned Media-Derived Exosomes Loaded With Extract Inhibit Lung Cancer via NF-κB and MAPK Pathway Modulation.负载提取物的间充质干细胞条件培养基衍生外泌体通过调节NF-κB和MAPK通路抑制肺癌
Food Sci Nutr. 2025 Aug 20;13(8):e70802. doi: 10.1002/fsn3.70802. eCollection 2025 Aug.
2
Natural Killer Cell-Secreted IFN-γ and TNF-α Mediated Differentiation in Lung Stem-like Tumors, Leading to the Susceptibility of the Tumors to Chemotherapeutic Drugs.自然杀伤细胞分泌的干扰素-γ和肿瘤坏死因子-α介导肺干细胞样肿瘤的分化，导致肿瘤对化疗药物敏感。
Cells. 2025 Jan 10;14(2):90. doi: 10.3390/cells14020090.
3
A Review of the Efficacy of Nanomaterial-Based Natural Photosensitizers to Overcome Multidrug Resistance in Cancer.基于纳米材料的天然光敏剂克服癌症多药耐药性的疗效综述
Pharmaceutics. 2024 Aug 24;16(9):1120. doi: 10.3390/pharmaceutics16091120.
4
Therapeutic Implications of PTEN in Non-Small Cell Lung Cancer.PTEN在非小细胞肺癌中的治疗意义
Pharmaceutics. 2023 Aug 5;15(8):2090. doi: 10.3390/pharmaceutics15082090.
5
A Systematic Role of Metabolomics, Metabolic Pathways, and Chemical Metabolism in Lung Cancer.代谢组学、代谢途径和化学代谢在肺癌中的系统性作用
Vaccines (Basel). 2023 Feb 7;11(2):381. doi: 10.3390/vaccines11020381.
6
Pten and p53 Loss in the Mouse Lung Causes Adenocarcinoma and Sarcomatoid Carcinoma.小鼠肺部的Pten和p53缺失导致腺癌和肉瘤样癌。
Cancers (Basel). 2022 Jul 28;14(15):3671. doi: 10.3390/cancers14153671.

本文引用的文献

1
Integrated Omics Analysis of Non-Small-Cell Lung Cancer Cells Harboring the EGFR C797S Mutation Reveals the Potential of AXL as a Novel Therapeutic Target in TKI-Resistant Lung Cancer.对携带EGFR C797S突变的非小细胞肺癌细胞进行综合组学分析揭示了AXL作为TKI耐药肺癌新治疗靶点的潜力。
Cancers (Basel). 2020 Dec 31;13(1):111. doi: 10.3390/cancers13010111.
2
Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies.聚焦ROS1阳性非小细胞肺癌（NSCLC）：克唑替尼、耐药机制及新一代靶向治疗
Cancers (Basel). 2020 Nov 6;12(11):3293. doi: 10.3390/cancers12113293.
3
An All-In-One Transcriptome-Based Assay to Identify Therapy-Guiding Genomic Aberrations in Nonsmall Cell Lung Cancer Patients.一种基于转录组的一体化检测方法，用于识别非小细胞肺癌患者的治疗指导基因组畸变。
Cancers (Basel). 2020 Oct 1;12(10):2843. doi: 10.3390/cancers12102843.
4
Positive Effects of Preventive Nutrition Supplement on Anticancer Radiotherapy in Lung Cancer Bearing Mice.预防性营养补充剂对荷肺癌小鼠抗癌放疗的积极作用。
Cancers (Basel). 2020 Aug 28;12(9):2445. doi: 10.3390/cancers12092445.
5
Targeting HER3, a Catalytically Defective Receptor Tyrosine Kinase, Prevents Resistance of Lung Cancer to a Third-Generation EGFR Kinase Inhibitor.靶向HER3（一种催化缺陷型受体酪氨酸激酶）可预防肺癌对第三代EGFR激酶抑制剂产生耐药性。
Cancers (Basel). 2020 Aug 24;12(9):2394. doi: 10.3390/cancers12092394.
6
Midkine Is a Potential Therapeutic Target of Tumorigenesis, Angiogenesis, and Metastasis in Non-Small Cell Lung Cancer.中期因子是非小细胞肺癌肿瘤发生、血管生成和转移的潜在治疗靶点。
Cancers (Basel). 2020 Aug 24;12(9):2402. doi: 10.3390/cancers12092402.
7
Resectable IIIA-N2 Non-Small-Cell Lung Cancer (NSCLC): In Search for the Proper Treatment.可切除的IIIA-N2期非小细胞肺癌（NSCLC）：探寻合适的治疗方法。
Cancers (Basel). 2020 Jul 25;12(8):2050. doi: 10.3390/cancers12082050.
8
Current Strategies for Treating NSCLC: From Biological Mechanisms to Clinical Treatment.治疗非小细胞肺癌的当前策略：从生物学机制到临床治疗
Cancers (Basel). 2020 Jun 15;12(6):1587. doi: 10.3390/cancers12061587.
9
Normalized Pulmonary Artery Diameter Predicts Occurrence of Postpneumonectomy Respiratory Failure, ARDS, and Mortality.标准化肺动脉直径可预测肺切除术后呼吸衰竭、急性呼吸窘迫综合征的发生及死亡率。
Cancers (Basel). 2020 Jun 10;12(6):1515. doi: 10.3390/cancers12061515.
10
Stereotactic Radiotherapy for Ultra-Central Lung Oligometastases in Non-Small-Cell Lung Cancer.立体定向放射治疗非小细胞肺癌超中央型肺寡转移灶
Cancers (Basel). 2020 Apr 5;12(4):885. doi: 10.3390/cancers12040885.